About Alpha-1

• Considering Alpha-1 Testing
• Newly Diagnosed with Alpha-1
• Living With Alpha-1

View AAT Deficiency and Lung Damage Animation

AlphaTest® Kit

Request our complimentary test kit from your doctor.

 

Alpha₁-antitrypsin (AAT) deficiency* – Alpha₁ – is an inherited condition in which there are low levels or no levels of AAT in the blood.

*Also known as AAT Deficiency, AATD, A₁-PI deficiency, alpha-1 antiprotease deficiency, A1AD, or hereditary or genetic emphysema.

Alpha₁-antitrypsin (AAT), also known as alpha₁-proteinase inhibitor (A₁-PI), is an enzyme produced by the liver and released into the bloodstream. One of the primary roles of AAT is to protect the lungs from neutrophil elastase (NE), an enzyme released by white blood cells. Neutrophil elastase can attack healthy lung tissue if not controlled by AAT.

Individuals with AAT deficiency are at high risk for developing emphysema. In addition, approximately 10% of infants and 15% of adults with AAT deficiency experience liver damage.¹

The American Lung Association estimates that there are about 100,000 people with AAT deficiency in the United States.²

ARALAST [Alpha₁-Proteinase Inhibitor (Human)] is indicated for chronic augmentation therapy in patients having congenital deficiency of A₁-PI with clinically evident emphysema. ARALAST is not indicated as therapy for lung disease patients in whom congenital A₁-PI deficiency has not been established.

Please review the Important Safety Information and the Full Prescribing Information